(CNN) – The Johnson & Johnson vaccine against covid-19 met the requirements for authorization for emergency use, according to an analysis published Wednesday by the U.S. Food and Drug Administration (FDA).
The efficacy of the Johnson & Johnson vaccine against moderate to severe / critical COVID-19 in all geographic areas was 66.9% at least 14 days after single dose vaccination and 66.1% at least 28 days after vaccination, according to a new analysis intended to report to the FDA Advisory Committee on Vaccines and Related Biologics.
WATCH: Pfizer, Moderna and Johnson & Johnson agree to produce 240 million doses of covid-19 vaccines for the US by the end of March.
“No specific safety concerns were identified in the subgroup analyzes for age, race, ethnicity, medical co-morbidity or prior SARS-CoV-2 infection,” the analysis said.
In an informational document, the FDA said it had reviewed the vaccine data and determined it “in line with the recommendations outlined in the FDA guidelines for the use of emergency vaccines to prevent COVID-19.
An independent group of FDA advisers, the Advisory Committee on Vaccines and Related Biologics, will consider the documents and make a recommendation on whether or not to permit vaccination against COVID-19. The committee will meet on Friday.
WATCH: Which Countries Have The Most Vaccinated In South America? The progress map, country by country